JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Lack of technology transfer stands out as a formidable barrier
New Board of Directors and management team at Suven Pharma also appointed
AHH will make an investment of Rs. 600 crore in the company through a mix of primary and secondary infusion
The approval is for acquisition of up to 76.1% equity shares of Suven Pharmaceuticals by Berhyanda Limited
AushadhAI is purposefully designed to deliver significant advantages to the pharmaceutical supply chain's key constituents
The newly launched Genomic Health Insights (GHI) program to make sequencing accessible to all
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
Pratima takes on the role of Country Speaker in addition to her role as GM and MD of Merck Specialties in India
Subscribe To Our Newsletter & Stay Updated